322 related articles for article (PubMed ID: 29736023)
1. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
Clément K; Biebermann H; Farooqi IS; Van der Ploeg L; Wolters B; Poitou C; Puder L; Fiedorek F; Gottesdiener K; Kleinau G; Heyder N; Scheerer P; Blume-Peytavi U; Jahnke I; Sharma S; Mokrosinski J; Wiegand S; Müller A; Weiß K; Mai K; Spranger J; Grüters A; Blankenstein O; Krude H; Kühnen P
Nat Med; 2018 May; 24(5):551-555. PubMed ID: 29736023
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
[TBL] [Abstract][Full Text] [Related]
4. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J
Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197
[TBL] [Abstract][Full Text] [Related]
5. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
[TBL] [Abstract][Full Text] [Related]
6. A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation.
Reininghaus N; Paisdzior S; Höpfner F; Jyrch S; Cetindag C; Scheerer P; Kühnen P; Biebermann H
Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009013
[TBL] [Abstract][Full Text] [Related]
7. Setmelanotide: First Approval.
Markham A
Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
[TBL] [Abstract][Full Text] [Related]
8. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
Falls BA; Zhang Y
ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice.
Kumar KG; Sutton GM; Dong JZ; Roubert P; Plas P; Halem HA; Culler MD; Yang H; Dixit VD; Butler AA
Peptides; 2009 Oct; 30(10):1892-900. PubMed ID: 19646498
[TBL] [Abstract][Full Text] [Related]
10. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
Kühnen P; Krude H; Biebermann H
Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
[TBL] [Abstract][Full Text] [Related]
11. Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype.
Kamermans A; Verhoeven T; van Het Hof B; Koning JJ; Borghuis L; Witte M; van Horssen J; de Vries HE; Rijnsburger M
Front Immunol; 2019; 10():2312. PubMed ID: 31636637
[TBL] [Abstract][Full Text] [Related]
12. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.
Kievit P; Halem H; Marks DL; Dong JZ; Glavas MM; Sinnayah P; Pranger L; Cowley MA; Grove KL; Culler MD
Diabetes; 2013 Feb; 62(2):490-7. PubMed ID: 23048186
[TBL] [Abstract][Full Text] [Related]
13. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides.
Marsh DJ; Hollopeter G; Huszar D; Laufer R; Yagaloff KA; Fisher SL; Burn P; Palmiter RD
Nat Genet; 1999 Jan; 21(1):119-22. PubMed ID: 9916804
[TBL] [Abstract][Full Text] [Related]
14. Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation.
Sharma S; Garfield AS; Shah B; Kleyn P; Ichetovkin I; Moeller IH; Mowrey WR; Van der Ploeg LHT
Molecules; 2019 May; 24(10):. PubMed ID: 31100979
[TBL] [Abstract][Full Text] [Related]
15. Temporal cAMP Signaling Selectivity by Natural and Synthetic MC4R Agonists.
Molden BM; Cooney KA; West K; Van Der Ploeg LH; Baldini G
Mol Endocrinol; 2015 Nov; 29(11):1619-33. PubMed ID: 26418335
[TBL] [Abstract][Full Text] [Related]
16. Control of appetite, blood glucose, and blood pressure during melanocortin-4 receptor activation in normoglycemic and diabetic NPY-deficient mice.
da Silva AA; Freeman JN; Hall JE; do Carmo JM
Am J Physiol Regul Integr Comp Physiol; 2018 Apr; 314(4):R533-R539. PubMed ID: 29351428
[TBL] [Abstract][Full Text] [Related]
17. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
[TBL] [Abstract][Full Text] [Related]
18. Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling.
Israeli H; Degtjarik O; Fierro F; Chunilal V; Gill AK; Roth NJ; Botta J; Prabahar V; Peleg Y; Chan LF; Ben-Zvi D; McCormick PJ; Niv MY; Shalev-Benami M
Science; 2021 May; 372(6544):808-814. PubMed ID: 33858992
[TBL] [Abstract][Full Text] [Related]
19. Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide.
Wabitsch M; Farooqi S; Flück CE; Bratina N; Mallya UG; Stewart M; Garrison J; van den Akker E; Kühnen P
J Endocr Soc; 2022 Jun; 6(6):bvac057. PubMed ID: 35528826
[TBL] [Abstract][Full Text] [Related]
20. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).
Hainer V; Aldhoon Hainerová I; Kunešová M; Taxová Braunerová R; Zamrazilová H; Bendlová B
Physiol Res; 2020 Sep; 69(Suppl 2):S245-S254. PubMed ID: 33094623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]